S-1 na capecitabine-geïnduceerde toxiciteit bij adjuvante colonkankerbehandeling: haalbaarheid en veiligheid

S-1 has comparable efficacy to capecitabine/5-FU in metastatic colorectal cancer, but is associated with a lower incidence of hand-foot syndrome (HFS) and cardiovascular toxicity (CVT). The European Medicines Agency has approved its use when capecitabine or 5-FU is discontinued due to HFS or CVT. However, in the adjuvant setting, data on its safety profile are scarce. We assessed the feasibility of S-1 in patients who discontinued capecitabine due to HFS or CVT.